SCCHN Study Program Flashcards
1
Q
Describe CONDOR
A
Phase II global multicentre, randomized, open label Second line SCCHN PD-L1- durva mono, treme mono, or combo (1:1:2) 240 patients overall, 60, 60, 120
2
Q
Describe EAGLE
A
Phase III, global, randomized, multicentre, open label
Second Line SCCHN
Patients who progressed within 6 mths of multimodal treatment with pt in the locally advanced setting
Any PD-L1 status
Durva mono vs combo vs SoC EXTREME (1:1:1)
~300 PD-L1+ patients (100 per group)
~420 PD-L1- patients (140 per group)
3
Q
Describe KESTREL
A
Phase III, global, multicentre, randomized, open label First line R/M SCCHN Any status PD-L1 Durva mono vs combo vs SoC EXTREME Number of patients unknown.
4
Q
Describe HAWK
A
Phase II, multicentre, global, single arm Second line SCCHN PD-L1+ Durva monotherapy 112 patients
